There is a pressing need for efficacious therapies in the field of respiratory diseases and
infections. Lipid nanocarriers, administered through aerosols, represent a promising tool for …

Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery.
With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …

Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery.
With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …

Administration of biologics such as proteins, vaccines, and phages via the respiratory route
is becoming increasingly popular. Inhalable powder formulations for the successful delivery …

For drug administration and delivery design, it is important to consider a number of factors,
but mainly the drug form and the administration route. The most depends on the …

Background: Delivery of inhalable nanoparticles through metered-dose inhalers (MDI) is a
promising approach to treat lung disease such as asthma and chronic obstructive pulmonary …

Inhaled delivery systems are promising tools for a safe administration of drugs in pulmonary
diseases. Two methods of administration to the lung can be distinguished: inhalation and …

Pulmonary delivery of antibiotics for the treatment of tuberculosis provides several benefits
compared to conventional oral and parenteral administration. API-loaded particles delivered …

Solid lipid nanoparticles (SLN) containing rifabutin (RFB), with pulmonary administration
purposes, were developed through a technique that avoids the use of organic solvents or …

Introduction: Treatment of lung diseases is one of the major healthcare challenges. Ferulic
acid (FA), a phenolic compound with well-established antioxidant and anti-inflammatory …